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Abstract 
Background: There are increasing reports on nosocomial Mycobacterium massiliense infection, but septic arthritis 
and osteomyelitis because of that microorganism is rare. This report focuses on the clinical aspects of M. massiliense 
arthritis outbreak concurrent with soft tissue infection.
Case presentation: An outbreak of septic arthritis among patients who had been injected at a single clinic occurred 
in South Korea between April and September 2012. This may be associated with repeated injection of triamcinolone 
contaminated with M. massiliense. Nine of the Korean patients visited our hospital complaining of painful swelling of 
the knees. During treatment course, patients are suffered from soft tissue abscess around the injection site. Acid‑fast 
bacilli culture for infected tissue was positive in five patients, and polymerase chain reaction for non‑tuberculous 
mycobacteria was positive in four patients. They were treated with antibiotics, repeated arthroscopic surgeries, 
incision and drainage for a long time. All patients were eventually cured but three patients have suffered from a 
decreased range of motion.
Conclusion: Early clinical suspicion and microbiological diagnosis are key factors in reducing morbidity since septic 
arthritis with M. massiliense manifests late after the injection and treatment of it is a laborious process.
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Background
Non-tuberculous mycobacteria (NTM) are ubiquitous in 
nature widely found in soil, wastewater, and other mate-
rials [1]. Mycobacterium massiliense, a rapidly growing 
mycobacteria (RGM), was first isolated from the sputum 
and bronchoalveolar lavage of a patient with pneumo-
nia in 2004 [2]. As a human pathogen, it can cause vari-
ous diseases including respiratory infections, abdominal 
infections, skin and soft tissue infections, especially local 
infections and abscesses after various surgeries or other 
procedures [3].
Recently, reports on nosocomial NTM outbreaks in 
various clinical situations have significantly increased. 
Because M. massiliense cases involving joints are 
scarce, we will focus on the clinical features, thera-
peutic experiences and prognosis of M. massiliense 
arthritis.
Case presentation
Two hundred forty four (19.3  %) patients of the 1264 
who had visited the primary local clinic from April 2012 
to September 2012 had one or more injections. Twenty-
seven cases were reported to the Korea Institute of Drug 
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Safety and Risk Management (KIDS) as adverse drug 
events by the physician at the clinic [4].
Our hospital is a 750-bedded tertiary medical center 
and major academic teaching hospital which is about 
16 km away from the clinic.
The nine Korean patients who had been injected at the 
clinic visited our hospital because of painful swelling of 
the knees. They all had a history of multiple intra-artic-
ular injections of the steroid mixed with analgesics in the 
same local clinic. They complained of fever (89 %), red-
ness (56 %), heating sensation (45 %), discharge (34 %) of 
infected site, and decreased range of motion (67 %). Eight 
of the patients were female and one patient was male. The 
mean age was 58.8 years (range 49–71 years). The median 
time from the injection date to the onset of symptoms 
was 4.7 weeks (range 2–9 weeks).
Joint fluid or infected tissues were obtained by needle 
aspiration or arthroscopic biopsy for Gram and Acid-fast 
bacilli (AFB) stain, bacterial and AFB culture, and poly-
merase chain reaction (PCR) for Mycobacterium tubercu-
losis (MTB) and NTM. Specimens were stained with the 
Auramine-rhodamine and Ziehl-Neelsen stain for AFB 
and plated onto Ogawa medium, BACTEC MGIT 960 
(Becton, Dickinson and Company), blood agar, and Mac-
Conkey agar.
In our hospital setting, MTB/NTM PCR is a real-time 
PCR which uses a primer that targets IS6110 which is a 
MTB specific gene, and a primer and a Taqman probe 
that targets an internal transcribed spacer (ITS) for 
identifying mycobacteria at the species level. So this can 
detect MTB and Mycobacterium genus through a single 
reaction.
We sent the same specimens to the Korean National 
Tuberculosis Association. They identified NTM by PCR-
restriction fragment length polymorphism (PCR-RFLP) 
analysis targeted to rpoB gene. They tested drug sus-
ceptibility by broth microdilution method, and reported 
minimum inhibitory concentration in accordance with 
Clinical and Laboratory Standards Institute guidelines.
Synovial fluid leukocyte was elevated in all patients 
(range 4770–28,800/μl), percentage of neutrophils was in 
the 10–95 % range, and higher than 65 % in four patients. 
AFB culture was positive in five patients, and PCR was 
positive for NTM in four patients. Result of AFB culture 
and PCR expressed as a positive or negative was same 
for all patients, except for one patient. AFB culture and 
MTB/NTM PCR of synovial fluid was not checked in one 
patient.
AFB stain of tissue obtained by arthroscopy was posi-
tive in two patients, AFB culture was positive in eight, 
and MTB/NTM PCR was positive in six. Microorgan-
ism was not identified in one patient. M. massiliense was 
finally detected in eight patients by using PCR-RFLP.
The antibiotics susceptibility test (Table  1) for M. 
massiliense was done in six isolates but was not checked 
in two isolates.
Magnetic resonance imaging was performed in eight 
of the nine patients. It showed a moderate to large joint 
effusion, intra-meniscal signal intensity change, dif-
fused synovial enhancement and thickening, and chon-
dral lesion with subchondral bone changes. In two of the 
patients, osteomyelitis was suspected due to increased 
bone marrow edema.
All patients were treated with combination of antibi-
otics for a long period, repeated arthroscopic irrigations 
and debridements. Three patients underwent arthro-
scopic adhesiolysis and six patients underwent brisement 
to improve contracture of the knee joint. All of them suf-
fered from accompanying skin and soft tissue abscesses 
around injection sites (knee, thigh, lower leg, buttocks 
and back) during treatment progress. Five patients 
were repeatedly admitted to our hospital due to recur-
rence of septic arthritis and soft tissue abscess despite 
maintenance of antibiotics. Incision and drainage for 
seven patients and excision for one was done to remove 
abscess. Patients underwent from one up to seven times 
of surgery.
Most arthroscopic findings revealed that synovium was 
hypertrophic and hyperemic because of inflammatory 
changes and multiple granulation tissues were filled-up. 
Damage of cartilage seemed to proceed slowly. Intra-
articular fat pad changes were seen because of fat tissue 
involvement with necrosis and discharge. The majority of 
abscesses tended to appear on the subcutaneous fat layer 
around injection sites. They appeared like masses and 
contained a turbid, yellowish discharge inside enclosed 
by a thickened capsule.
Empirical antibiotics were intravenous (IV) vanco-
mycin plus anti-pseudomonal third generation cepha-
losporin (ceftazidime) to cover Staphylococcus aureus 
especially for methicillin resistant S. aureus or Pseu-
domonas aeruginosa which are important pathogens 
related with the procedures. After confirming that PCR 
was positive for NTM, some patients were treated with 
oral clarithromycin, IV amikacin and imipenem for RGM. 
After the culture confirmed the existence of M. massil-
iense, we maintained the combination of oral clarithro-
mycin, IV amikacin and imipenem for six patients. For 
two patients whose drug susceptibility were not ana-
lyzed and another patient whose tissue culture revealed 
no organism, we treated them with the same antibiotics 
based on the epidemic circumstances. Complications 
associated with antibiotics did occur like dizziness in 
seven patients, hearing deterioration in three, tinnitus 
in two and otalgia in one. We could not keep amikacin 
due to high tone hearing loss in four patients and acute 
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kidney injury in one patient. One patient complained of 
nausea and vomiting because of the imipenem.
The average duration of medical treatment among the 
nine patients except that of empirical antibiotics was 
382.9 days (range 174–776 days). Details on the charac-
teristics of patient, treatment course and outcome are 
presented in Table 2. All patients were eventually cured 
but three patients kept on complaining of a decreased 
range of motion.
Discussion
Mycobacterium abscessus complex is RGM character-
ized by growth in solid agar media within seven days 
and subclassified into three closely related subspe-
cies of M. abscessus, M. massiliense, and M. bolletii [1]. 
M. massiliense has an identical 16S ribosomal RNA 
(rRNA) sequence that of M. abscessus but can be dif-
ferentiated from M. abscessus by using hsp65, rpoB, 
sodA, recA genes and 16S–23S rRNA ITS sequences [2]. 
Because of the close relationship between M. abscessus 
and M. massiliense, it is possible that M. massiliense had 
been misidentified as M. abscessus in previous studies. In 
one study, M. massiliense constitutes a large proportion 
of RGM isolates previously identified as M. abscessus [5].
Mycobacterium massiliense has a different pattern 
of erythromycin ribosomal methylase (erm) gene from 
M. abscessus, and showed a good response to the 
clarithromycin-containing regimen [1]. Because the 
susceptibility to clarithromycin of M. massiliense dif-
fers from M. abscessus, distinguishing between the two 
organisms is clinically important.
Recently, there have been increasing reports on 
M. abscessus complex soft tissue infections in immuno-
competent people. This is resistant to disinfectants, and 
easily forms biofilm which can cause post-surgical and 
post-procedural infections. Contaminated materials 
(reusable needles or syringes, diluents for injection, wash 
water for injector, and inappropriate disinfectant) play an 
important role in nosocomial infections [4]. Soft tissue 
infections caused by M. massiliense have been reported 
associated with pacemaker pocket infections [6], intra-
muscular injections [7], arthroscopic, laparoscopic [3] 
and cosmetic procedures [8].
This report describes the first outbreak of septic arthri-
tis due to M. massiliense associated with intra-articular 
injections administered at a local clinic, in Seoul, South 
Korea. Among the 244 patients who were injected at 
the clinic, 61 patients were participated in the analysis 
conducted by KIDS and Korea Center for Disease Con-
trol and Prevention [4] and 9 patients of the 61 were 
hospitalized in our hospital. All septic arthritis patients 
were injected with triamcinolone. The triamcinolone 
injection agent was prepared by mixing 0.5  ml of tri-
amcinolone from a 1 ml container, 1 ml of saline from a 
20 ml container and 1 ml of lidocaine from a 20 ml con-
tainer. These containers were reused later. The nursing 
assistant injected the agent into multiple sites using a 
single syringe without wearing gloves. No microorgan-
ism was identified in the environmental samples, empty 
vials, injection medications, injection needles, syringes 
and alcohol swabs. However, the reuse of triamcinolone 
contaminated with M. massiliense from the clinic envi-
ronment and repeated injection may have affected this 
post-injection outbreak. Insufficient sterilization (hand 
washing, wearing gloves, appropriate skin disinfec-
tion, soaking cotton balls in appropriate disinfectant but 
not boiled tap water, aseptic preparation of the injec-
tion agent, and procedure) have possibly contributed 
to an increase of the risk of infection. It was likely that 
the risk factors for septic arthritis including advanced 
Table 1 Results of drug susceptibility test against Mycobacterium massiliense
AK amikacin, CFX cefoxitin, CIP ciprofloxacin, CLA clarithromycin, DOX doxycycline, IMP imipenem, MXF moxifloxacin, TMP/SMX trimethoprim/sulfamethoxazole, LNZ 
linezolid, S susceptible, I intermediate, R resistant
Minimum inhibitory concentration (μg/ml) of antibiotics
Patient number AK CFX CIP CLA DOX IMP MXF TMP/
SMX
LNZ
1 16 S 32 I 8 R ≤0.5 S 32 R 8 I 2 I 4/76 R ≤2 S
2 16 S 32 I 4 R ≤0.5 S 8 R 8 I 2 I 8/152 R 4 S
3 Not checked
4 16 S 64 I 16 R ≤0.5 S 16 R 16 I 4 R 16/304 R 8 S
5 16 S 16 S 8 R ≤0.5 S >32 R 4 S 2 I 4/76 R 4 S
6 Not isolated
7 Not checked
8 8 S 32 I 8 R ≤0.5 S >32 R 4 S 4 R 4/76 R ≤2 S
9 16 S 16 S 16 R ≤0.5 S >32 R 8 I 8 R 8/152 R 4 S
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Table 2 Patient characteristics, treatment and outcome






1e F/54 Breast cancer Six 4 Cefazolin (2 days)
Ceftazidime 
(8 days) + vancomycin 
(3 days) → ceftazi 
dayime + teicoplanin 
(2 days)
Amikacin 
(68 days) + imipenem 





Readmission due to knee 
abscess
 Imipenem 
(8 days) + clarithromy‑
cin (137 days)
 Arthroscopic irrigation 
and debridement




2 F/51 Hypertension Six 4 Cefazolin (2 days)
Ceftazidime 
(7 days) + vancomycin 
(7 days)
Amikacin 
(30 days) + imipenem 




Incision and drainage 






Readmission due to 
thigh, calf abscesses
 Imipenem 
(12 days) + clarithro‑
mycin (92 days)
 Incision and drainage of 
abscesses
Full
3 F/56 Diabetes mellitus Two 6 Cefazolin (4 days)
Ceftazidime 
(3 days) + vancomycin 
(3 days)
Amikacin 
(34 days) + imipenem 






Open excision of back 
abscess
Full
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Table 2 continued






4 F/65 Diabetes mellitus Multiple
(above eight)
7 Cefazolin (1 day)
Ceftazidime 
(2 days) + vancomycin 
(2 days)
Amikacin 
(29 days) + imipenem 




Excision of thigh abscess
Incision and drainage of 
back abscess
Full
5 F/59 Subclinical hypothy‑
roidism
Four 3 Cefazolin (1 day)
Ceftazidime 
(3 days) + vancomycin 
(3 days)
Amikacin 
(27 days) + imipenem 






Readmission due to 
recurrence of septic 
arthritis and buttock 
abscess
 Imipenem 
(25 days) + clarithro‑
mycin (160 days)
 Arthroscopic irrigation 
and debridement





Fivec 2 Ceftazidime 
(3 days) + vancomycin 
(3 days)
Amikacin 
(29 days) + imipenem 







Two 5–9 (assumedd) Ceftazidime 
(1 day) + vancomycin 
(1 day)
Amikacin 
(27 days) + imipenem 




Incision and drainage 
(X5) of popliteal fossa, 
both buttock, thigh 
and knee abscesses
Brisement
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Table 2 continued










Multiple (above six) 3 Cefazolin (1 day)
Ceftazidime 
(3 days) + vancomycin 
(3 days)
Amikacin 
(16 days) + imipenem 




Excision and revision of 
necrotic wounds of 
neck, back




Incision and drainage of 
neck, back abscesses
Readmission due to 
abscesses of multiple 
sites
 Imipenem 
(34 days) + clarithro‑
mycin (98 days)
 Arthroscopic irrigation 
and debriment
 Incision and drainage of 
neck, back, buttock and 
leg abscesses
Outpatient clinic follow 
up due to abscesses of 
multiple sites
 Imipenem 
(15 days) + clarithro‑
mycin (62 days) + levo‑
floxacin (28 days)
Readmission due to Rt. 
leg, back abscesses
 Imipenem 
(25 days) + clarithro‑
mycin (29 days)
 Incision and drainage, 
excision of abscesses
Outpatient clinic follow 
up due to abscesses of 
multiple sites
 Clarithromycin 
(77 days) + linezolid 
(57 days)
 Amikacin 
(20 days) + imipenem 
(20 days) + clarithro‑
mycin (294 days)
 Clarithromycin 
(99 days) + doxycycline 
(99 days)
Full
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age, comorbidities such as rheumatoid arthritis, oste-
oarthritis, and diabetes mellitus played a role in the 
M. massiliense infection. The cessation of outbreak was 
well correlated with a closure of the clinic [4].
Combination therapy of IV amikacin with cefoxitin or 
imipenem and an oral macrolide such as clarithromycin, 
azithromycin is recommended for M. abscessus by the 
American Thoracic Society/Infectious Diseases Society 
of America [9] and is applied for M. massiliense in many 
centers. However, treatment of it is an increasingly fre-
quent challenge to clinicians, because of the extended 
treatment duration, use of multiple antimicrobial agents 
and drug related toxicities. Surgical debridement remains 
an important element of successful therapy especially for 
extensive disease, necrosis, or abscesses. Surgical exci-
sion or drainage combined with a backbone of clarithro-
mycin for 3–6 months appeared to be the most suitable 
therapy for post-injection abscess [10].
Since septic arthritis with NTM manifests several days 
up to months after the injection, and empirical thera-
peutic approaches commonly used to treat soft tissue 
infections are not effective against NTM, early clinical 
Table 2 continued






9h F/49 Osteoarthritis Multiple 5–8 (presumedd) Amikacin 
(6 days) + imipenem 










Incision and drainage of 
knee abscess
Clarithromycin 
(88 days) + linezolid 
(14 days)
Readmission due to 
recurrence of septic 
arthritis
Cefoxitin 
(13 days) + amikacin 
(13 days) + clarithro‑
mycin (182 days)
Readmission due to knee 
abscess and recurrence 
of septic arthritis
 Cefoxitin 
(38 days) + amikacin 
(38 days) + clarithromy‑
cin (178 days) + [cipro‑
floxacin (9 days) → lev‑
ofloxacin (148 days)]
 Excision of knee abscess
Full
a  Incubation period means time between exposure to first injection and appearance of the first symptoms
b   We list antibiotics before and surgeries later with a number in the order, and assign new number if patient readmitted. We indicate duration of antibiotics and 
number of surgeries in parenthesis. The alphabet “d” in parenthesis following antibiotics is abbreviation for day
c  The patient had four injections by the original clinic and one injection by a different private clinic after the onset of symptoms
d  Patients could not recall the exact onset of the symptoms and recalled on a monthly basis rather than weekly. So we set incubation period from the first week to 
last week on the basis of their memory
e  Vancomycin was stopped due to drug fever and was replaced by teicoplanin
f  Small abscesses of both knees appeared when the patient followed up observations in an outpatient setting. We recommended her admission but she refused
g  The patient was discharged against medical advice and did not return due to financial limitations
h   The patient was treated with isoniazid, rifampin, ethambutol and pyrazinamide for 6 days at another hospital before visiting our hospital. We changed imipenem 
to cefoxitin because of nausea, vomiting. The patient was further readmitted twice due to postoperative pus discharge and knee abscess recurrence in spite of 
maintenance of oral clarithromycin and ciprofloxacin replaced with levofloxacin
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suspicion and microbiological diagnosis are key factors in 
reducing morbidity [3].
Conclusion
In our cases, the patients were treated with long term 
IV and oral antibiotics combined with repeated surgical 
interventions. The duration of the oral clarithromycin 
treatment ranged from 174 to 776 days. Patients under-
went repeated surgeries up to seven times. Although 
M. massiliense is an emerging pathogen of soft tissue 
infection associated with procedure or surgery, septic 
arthritis and osteomyelitis rarely occur and its clinical 
information and therapeutic options are still not fully 
understood. We report this outbreak of septic arthritis 
by M. massiliense with characteristics of patients, clini-
cal manifestations, laboratory and synovial fluid analysis, 
treatment duration and progress, highlight the difficulty 
in treating the M. massiliense infection and expect it to 
be a help in the diagnosis and treatment of septic arthritis 
caused by M. massiliense.
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